OptimizeRx Welcomes Andrew D’Silva as Senior Vice President of Corporate Finance

0

D’Silva brings over 10 years of equity research experience

ROCHESTER, Mich., Sept. 08, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has appointed Andrew D’Silva to the new role of Vice- Chairman and Chief Corporate Finance Officer.

D’Silva will be responsible for assisting the Company with its strategic growth and capital markets initiatives. He will also work alongside OptimizeRx’s business and finance teams to design capital allocation strategies to further drive growth.

“We are very pleased to welcome Andrew to the OptimizeRx family. With a deep background in capital markets, he has a strong track record as a top industry analyst,” said OptimizeRx CEO, William Febbo “Andrew has a deep understanding of the health technology industry and a keen sense of what makes a winner in the space. He will play a key role in supporting our organic and inorganic growth,” concluded Mr. Febbo.

The OptimizeRx digital health technology platform connects life sciences treatment support at all stages of a patient’s care journey, and helps people pay for and stay on course through the recommended course of treatment by the doctor. The Company is increasingly aligning with the pharmaceutical industry in key specialty therapeutic areas and has continued to expand its omnichannel network of point-of-care solutions for patients, physicians and life sciences.

“I have watched OptimizeRx execute its various growth initiatives for the better part of a decade and am truly honored to join the team,” commented D’Silva. “I have been impressed with the company’s ability to act with agility in a rapidly changing industry while leveraging its platform to execute on its vision of improving affordability, access and convenience. compliance, which ultimately leads to better health outcomes. I look forward to leveraging my industry experience to help OptimizeRx further expand its reach into the life sciences and omnichannel space. »

D’Silva has over a decade of equity and capital markets research experience and most recently served as a senior healthcare research analyst at B. Riley Securities. Earlier in his career, he was Managing Director and a member of the equity research team at Merriman Capital.

D’Silva earned a bachelor’s degree in economics from the University of California, San Diego.

About OptimizeRx
OptimizeRx is a digital health company that provides communication solutions for life science companies, physicians and patients. Connecting more than half of US healthcare providers and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients pay for and stay on their medications. The platform opens up new patient and physician touchpoints for life science companies across the patient journey, from point-of-care to retail pharmacy to mobile patient engagement.

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements should not be relied upon to make an investment decision. The words “estimate”, “possible” and “seek” and similar expressions identify forward-looking statements, which speak only as of the date on which the statement was made. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those stated, contemplated or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact OptimiserRx
Doug Baker, Chief Financial Officer
Tel (248) 651-6568 (x807)
[email protected]

Contact person for media relations
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
[email protected]

Investor Relations
Ashley Robinson
LifeSci Advisors, LLC
[email protected]

Share.

Comments are closed.